With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Transcript
How are community oncology practices handling the challenge of stocking multiple biosimilars for the same reference product and balancing the needs of various payers?
Fortunately, those issues play to the power of community oncology, and particularly Rocky Mountain Cancer Centers. We have a strong clinical pharmacy team—they work very closely with our managed care team. To your point, some payers are now preferring a particular product vs another. In the old days, we could have one type of medication in that class, but now we're going to have to keep inventory with multiple.
That takes a strong pharmacy-led team. It takes strong education on the pharmacy techs. It takes strong leadership from the managed care team. That communication piece is vital. Once the physicians got buy-in—they trusted the process—I think we're well positioned to handle this transformation, which is happening in real time.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More